

Remarks

Claims 1-29 have been canceled without prejudice or disclaimer. Applicants reserve the right to pursue subject matter encompassed by all canceled claims in one or more divisional or continuation applications. Claims 30-57 have been added to expand the embodiments of the elected subject matter. No new matter has been added.

Claims 30-57 are supported by the specification and claims as originally filed. For example, support for claims 30-57 can be found in the specification at: page 33, paragraph [0097] to page 37, paragraph [0111] (post-translational modifications; glycosylation; chemical moiety; polyethylene glycol; enzyme label; and fluorescent label); page 46, paragraph [0135] to page 47, paragraph [0136] (90%; extracellular domain; 8-41 amino acids; 1-54 amino acids); page 50, paragraph [0142] to paragraph [0144] (90%; 4-44 amino acids; 4-52 amino acids; 4-54 amino acids); page 56, paragraph [0159] (protein fusions; human immunoglobulin constant domains or fragments thereof); pages 125 to 126, paragraph [0330] (autoimmune disease; Sjorgen's Syndrome; Reiter's Disease; Guillain-Barre Syndrome; Hashimoto's thyroiditis; Addison's disease; biliary cirrhosis; asthma); and page 139, paragraph [0370] (radioisotopes). Accordingly, no new matter has been added.

Restriction Requirement/Election

A restriction requirement has been issued in which claims 1-29 were separated into eight different groups. *See*, Paper No. 20060825, page 2.

To comply with the pending restriction requirement, Applicants herein elect claims embodying the subject matter restricted to Group IV (*i.e.*, a method of treatment by administration of the polypeptides of the invention). New claims 30-57 have been added to more fully expand the embodiments of the elected subject matter. The subject matter encompassed by these claims fall within the ambit of Group IV as cast by the Examiner. *See*, Paper No. 20060825, pages 6, fourth paragraph.

Conclusion

Applicants respectfully request that the amendments and remarks submitted herein be entered in the present application. The Examiner is invited to call the undersigned at the phone number provided below if any further action by Applicants would expedite the examination of this application.

If there are any fees not already accounted for due in connection with the filing of this paper, please charge the fees to our Deposit Account No. 08-3425. If a fee is required for an extension of time under 37 C.F.R. § 1.136, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: Jan 25, 2007

Respectfully submitted,

By 

Melissa J. Pytel

Registration No.: 41,512
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 610-5764

MJP/DBS/ba